SG11201907298WA - Methods and compositions for gene transfer across the vasculature - Google Patents
Methods and compositions for gene transfer across the vasculatureInfo
- Publication number
- SG11201907298WA SG11201907298WA SG11201907298WA SG11201907298WA SG11201907298WA SG 11201907298W A SG11201907298W A SG 11201907298WA SG 11201907298W A SG11201907298W A SG 11201907298WA SG 11201907298W A SG11201907298W A SG 11201907298WA SG 11201907298W A SG11201907298W A SG 11201907298WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- north
- pct
- publication
- date
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459286P | 2017-02-15 | 2017-02-15 | |
| PCT/US2018/018381 WO2018152333A1 (fr) | 2017-02-15 | 2018-02-15 | Méthodes et compositions pour le transfert de gènes à travers le système vasculaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907298WA true SG11201907298WA (en) | 2019-09-27 |
Family
ID=63169716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907298WA SG11201907298WA (en) | 2017-02-15 | 2018-02-15 | Methods and compositions for gene transfer across the vasculature |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11905312B2 (fr) |
| EP (1) | EP3583220A4 (fr) |
| JP (2) | JP7291397B2 (fr) |
| KR (1) | KR20190117571A (fr) |
| CN (1) | CN110520536A (fr) |
| AU (1) | AU2018221738A1 (fr) |
| BR (1) | BR112019016769A2 (fr) |
| CA (1) | CA3052829A1 (fr) |
| EA (1) | EA038695B1 (fr) |
| IL (1) | IL268534A (fr) |
| MX (1) | MX2019009720A (fr) |
| SG (1) | SG11201907298WA (fr) |
| WO (1) | WO2018152333A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| JP7064214B2 (ja) | 2015-09-28 | 2022-05-10 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 抗体回避性ウイルスベクターのための方法および組成物 |
| CN111163811A (zh) * | 2017-08-25 | 2020-05-15 | 奥维德医疗公司 | 重组腺相关载体 |
| EP3774854A1 (fr) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Vecteurs de virus évitant les anticorps |
| WO2019217911A1 (fr) | 2018-05-11 | 2019-11-14 | Massachusetts Eye And Ear Infirmary | Tropisme hépato-spécifique de virus adéno-associés |
| JP2021530218A (ja) | 2018-07-11 | 2021-11-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| KR20210084459A (ko) | 2018-09-26 | 2021-07-07 | 캘리포니아 인스티튜트 오브 테크놀로지 | 표적화된 유전자 요법을 위한 아데노-연관 바이러스 조성물 |
| EA202192501A1 (ru) | 2019-03-21 | 2021-12-16 | Страйдбайо, Инк. | Рекомбинантные аденоассоциированные вирусные векторы |
| TW202102526A (zh) * | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | 重組腺相關病毒及其用途 |
| CA3151021A1 (fr) * | 2019-08-14 | 2021-02-18 | University Of Florida Research Foundation, Incorporated | Variants capsidiques d'aav pour therapie genique |
| CA3153972A1 (fr) * | 2019-09-09 | 2021-03-18 | Massachusetts Eye And Ear Infirmary | Methodes et compositions de modulation de l'interaction entre un virus adeno-associe (aav) et le recepteur d'aav (aavr) a des fins de bio-distribution modifiee d'aav |
| WO2021076925A1 (fr) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Vecteurs de virus adéno-associés pour le traitement de la maladie de niemann-pick de type c |
| US20220411821A1 (en) * | 2019-10-28 | 2022-12-29 | University Of Florida Research Foundation, Incorporated | Gene therapy vectors |
| US20230346981A1 (en) * | 2019-11-22 | 2023-11-02 | The Children's Hospital Of Philadelphia | Adeno-associated viral vector variants |
| WO2021142300A2 (fr) * | 2020-01-10 | 2021-07-15 | The Brigham And Women's Hospital, Inc. | Procédés et compositions pour l'administration d'agents d'immunothérapie à travers la barrière hémato-encéphalique pour traiter le cancer du cerveau |
| WO2021163357A2 (fr) | 2020-02-13 | 2021-08-19 | Tenaya Therapeutics, Inc. | Vecteurs de thérapie génique de traitement de maladie cardiaque |
| KR20220139956A (ko) | 2020-02-13 | 2022-10-17 | 테나야 테라퓨틱스, 인코포레이티드 | 심장 질환을 치료하기 위한 유전자 요법 벡터 |
| CN115836081A (zh) * | 2020-02-25 | 2023-03-21 | 儿童医学研究院 | 腺相关病毒衣壳多肽及载体 |
| WO2022076750A2 (fr) * | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Virus adéno-associés recombinants pour administration musculaire ou dans le snc |
| US20240060087A1 (en) * | 2021-01-08 | 2024-02-22 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav |
| US20240082351A1 (en) * | 2021-01-13 | 2024-03-14 | Duke University | Compositions for and methods of improving fluid flux in the brain |
| US20230133924A1 (en) | 2021-07-08 | 2023-05-04 | Tenaya Therapeutics, Inc. | Optimized expression cassettes for gene therapy |
| WO2023288184A2 (fr) * | 2021-07-14 | 2023-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions et méthodes de traitement de la douleur chronique et de transduction rétrograde de neurones |
| CN113480615B (zh) * | 2021-07-30 | 2022-05-31 | 上海信致医药科技有限公司 | 高视网膜亲和性的新型腺相关病毒衣壳蛋白及其应用 |
| CN113563430B (zh) * | 2021-07-30 | 2022-05-31 | 上海信致医药科技有限公司 | 用于治疗眼部疾病的基因递送系统及其应用 |
| WO2023023781A1 (fr) * | 2021-08-25 | 2023-03-02 | Children's Medical Research Institute | Polypeptides et vecteurs capsidiques de vaa modifiés |
| WO2023060272A2 (fr) * | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Virus adéno-associés recombinants pour administration tropique au snc |
| CN114516901B (zh) * | 2022-03-11 | 2023-01-17 | 上海勉亦生物科技有限公司 | 一种神经系统高亲和性的aav载体及其应用 |
| WO2023201277A1 (fr) * | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Virus adéno-associés recombinants pour administration tropique au snc |
| WO2024054864A1 (fr) | 2022-09-06 | 2024-03-14 | Tenaya Therapeutics, Inc. | Thérapies cardioprotectrices contre les maladies cardiaques |
| KR20240048599A (ko) * | 2022-10-06 | 2024-04-16 | 주식회사 글루진테라퓨틱스 | 폐 기관지 특이적 유전자 전달이 가능한 아데노부속바이러스 벡터 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6491907B1 (en) * | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| NZ561656A (en) | 2002-05-01 | 2009-03-31 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
| US8889641B2 (en) * | 2009-02-11 | 2014-11-18 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| WO2013078400A1 (fr) * | 2011-11-22 | 2013-05-30 | The Children's Hospital Of Philadelphia | Vecteurs viraux pour administration de transgènes hautement efficace |
| CN111621507A (zh) * | 2012-09-28 | 2020-09-04 | 北卡罗来纳-查佩尔山大学 | 靶向少突胶质细胞的aav载体 |
| EP3151866B1 (fr) * | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Capsides chimériques |
| WO2017015102A1 (fr) * | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Compositions et procédés pour obtenir des niveaux élevés de transduction dans des cellules hépatiques humaines |
-
2018
- 2018-02-15 AU AU2018221738A patent/AU2018221738A1/en active Pending
- 2018-02-15 WO PCT/US2018/018381 patent/WO2018152333A1/fr unknown
- 2018-02-15 EA EA201991911A patent/EA038695B1/ru unknown
- 2018-02-15 KR KR1020197025393A patent/KR20190117571A/ko not_active Application Discontinuation
- 2018-02-15 BR BR112019016769-2A patent/BR112019016769A2/pt unknown
- 2018-02-15 JP JP2019542561A patent/JP7291397B2/ja active Active
- 2018-02-15 MX MX2019009720A patent/MX2019009720A/es unknown
- 2018-02-15 CN CN201880025093.XA patent/CN110520536A/zh active Pending
- 2018-02-15 SG SG11201907298WA patent/SG11201907298WA/en unknown
- 2018-02-15 EP EP18754551.2A patent/EP3583220A4/fr active Pending
- 2018-02-15 CA CA3052829A patent/CA3052829A1/fr active Pending
- 2018-02-15 US US16/485,094 patent/US11905312B2/en active Active
-
2019
- 2019-08-06 IL IL268534A patent/IL268534A/en unknown
-
2023
- 2023-01-20 JP JP2023007075A patent/JP2023052541A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190367562A1 (en) | 2019-12-05 |
| AU2018221738A1 (en) | 2019-08-22 |
| EP3583220A1 (fr) | 2019-12-25 |
| EA038695B1 (ru) | 2021-10-06 |
| CA3052829A1 (fr) | 2018-08-23 |
| US11905312B2 (en) | 2024-02-20 |
| IL268534A (en) | 2019-09-26 |
| JP2023052541A (ja) | 2023-04-11 |
| EP3583220A4 (fr) | 2021-07-07 |
| BR112019016769A2 (pt) | 2020-05-26 |
| CN110520536A (zh) | 2019-11-29 |
| MX2019009720A (es) | 2019-10-07 |
| WO2018152333A1 (fr) | 2018-08-23 |
| WO2018152333A9 (fr) | 2019-01-24 |
| JP7291397B2 (ja) | 2023-06-15 |
| KR20190117571A (ko) | 2019-10-16 |
| EA201991911A1 (ru) | 2020-02-20 |
| JP2020505936A (ja) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907298WA (en) | Methods and compositions for gene transfer across the vasculature | |
| SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201809684YA (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
| SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201805680SA (en) | Methods and compositions for the treatment of neurologic disease | |
| SG11201805835WA (en) | Modified oncolytic virus | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201806392XA (en) | Personalized delivery vector-based immunotherapy and uses thereof |